Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
DURHAM, N.C., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (NASDAQ:DTIL), a genome editing company dedicated to improving life through the application of its pioneering, proprietary ARCUS® platform, announced today that it will publish financial results for the third quarter of 2019 and provide a corporate update on November 12, 2019.
In addition, members of Precision BioSciences senior leadership will present at three investor conferences in November. Precision BioSciences CEO, Matt Kane, will also participate in a panel discussion at the Barclays Gene Editing & Gene Therapy Summit.
Barclays Gene Editing & Gene Therapy Summit
Date: November 13, 2019
Presentation Time: 2:45 p.m. ET
Panel Time: 4:15 p.m. ET
Location: New York, NY
Speakers: Matt Kane, Chief Executive Officer
Stifel Healthcare Conference
Date: November 20, 2019
Presentation Time: 2:25 p.m. ET
Location: New York, NY
Speakers: Abid Ansari, Chief Financial Officer and Derek Jantz, PhD, Chief Scientific Officer
Jefferies London Healthcare Conference
Date: November 20, 2019
Presentation Time: 12:40 p.m. GMT
Location: London, UK
Speakers: Matt Kane, Chief Executive Officer
A live audio webcast of the Jefferies presentation will be available here (webcast link) and up-to-date details for each event can be found on the "Events & Presentations" page in the Investors section of the Precision BioSciences website (www.precisionbiosciences.com). A replay of the Jefferies presentation will also be archived for 90 days on the Events & Presentations page.
About Precision BioSciences, Inc.
Precision BioSciences is dedicated to improving life (DTIL) through its proprietary genome editing platform, ARCUS. Precision leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and create healthy and sustainable food and agriculture solutions. Precision is actively developing product candidates in three innovative areas: allogeneic CAR T immunotherapy, in vivo gene correction, and food. For more information regarding Precision, please visit www.precisionbiosciences.com.
Investor Contact:
Nick Riddle
Precision BioSciences
Tel. (919) 314-5512
IR@precisionbiosciences.com
Media Contact:
Cory Tromblee
Scient Public Relations
Tel. (617) 571-7220
cory@scientpr.com
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!